01513 LIVZON PHARMA
- 29.000
- +2.750+10.48%
LIVZON PHARMA News
Livzon Pharmaceuticals (01513.HK): Cetrorelix acetate for injection was approved by the US FDA
On April 26, GLONGHUI Pharmaceutical (01513.HK) issued an announcement. Recently, Lizhu Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an ANDA approval notice (ANDA number: 214540) issued by the US Food and Drug Administration (hereinafter referred to as the “US FDA”) to approve the marketing and sale of injectable cetrorelix acetate developed by the company in the US.
Pearl Pharmaceuticals (01513) spent HK$436,300 to buy back 16,700 shares on April 25
According to the Zhitong Finance App, Lizhu Pharmaceutical (01513) announced that on April 25, 2024, the company spent HK$436,300 to repurchase 16,700 shares at a repurchase price of HK$26-26.15 per share.
Pearl Pharmaceuticals (01513) spent about HK$7.3579 million to buy back 285,800 shares on April 24
Pearl Pharmaceuticals (01513) announced that on April 24, 2024, it cost approximately HK$7.3579 million to repurchase 28...
Livzon Pharmaceutical's Q1 Profit Jumps 4.5%; Revenue Slips 5%
Livzon Pharmaceutical Group's (HKG:1513, SHE:000513) attributable profit rose 4.45% to 607.8 million yuan in the first quarter from 581.9 million yuan in the year-ago period, according to a Wednesday
Lizhu Pharmaceutical (01513.HK)'s net profit of 608 million yuan in the first quarter increased 4.45% year-on-year
Gelonghui, April 23 | Lizhu Pharmaceutical (01513.HK) announced that in the first quarter of 2024, the company achieved operating income of 3.243 billion yuan in the first quarter, a year-on-year decrease of 4.99%; net profit to mother was 608 million yuan, up 4.45% year on year; and basic earnings per share were 0.65 yuan.
麗珠醫藥：2024年第一季度報告
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Livzon Pharmaceuticals (01513.HK) plans to hold a board meeting on April 23 to approve quarterly results
Gelonghui, April 11, 丨 Lizhu Pharmaceutical (01513.HK) issued an announcement. The board of directors hereby announces that it will hold a board meeting on April 23, 2024 (Tuesday) to review and approve the unaudited quarterly results of the company and its subsidiaries for the three months ended March 31, 2024, and to deal with other matters.
Livzon Pharmaceutical Group (SZSE:000513) Shareholders Have Earned a 11% CAGR Over the Last Five Years
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For exa
Pearl Group (000513.SZ) has repurchased a total of 2.152,600 A-share shares at a cost of 73.436,500 yuan
Pearl Group (000513.SZ) issued an announcement. As of March 31, 2024, the company passed centralized bidding...
Pearl Pharmaceuticals (01513) plans to renew its employment with Tong Certified Public Accountants
Lizhu Pharmaceutical (01513) announced that the company plans to renew the employment of Certified Public Accountants (Special General Partnership) as the company...
Livzon Pharmaceuticals (01513) released annual results, net profit of 1,954 billion yuan, an increase of 2.32% year-on-year
Livestock Pharmaceuticals (01513) announced the audited results for the year ended December 31, 2023. During the period...
LIVZON PHARMA: ANNOUNCEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Pearl Group (000513.SZ): Net profit for 2023 increased 2.32% to 1,954 billion yuan, and plans to distribute 10 to 13.5 yuan
On March 28, Ge Longhui Group (000513.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 12.430 billion yuan, a year-on-year decrease of 1.58%; net profit attributable to shareholders of listed companies was 1,954 billion yuan, up 2.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,881 billion yuan, an increase of 0.05% year on year; basic income per share was 2.10 yuan; it plans to distribute cash dividends of RMB 13.50 yuan (tax included) to all shareholders of the company for every 10 shares.
Livzon Pharmaceuticals (01513) will pay a final dividend of $13.5 for every 10 shares on August 5
Livzon Pharmaceuticals (01513) announced that it will pay a final dividend of 13.5 yuan for every 10 shares on August 5, 2024...
Are Strong Financial Prospects The Force That Is Driving The Momentum In Livzon Pharmaceutical Group Inc.'s SZSE:000513) Stock?
Livzon Pharmaceutical Group's (SZSE:000513) stock is up by a considerable 13% over the past three months. Given that the market rewards strong financials in the long-term, we wonder if that is the c
Livingstone Group (000513.SZ): 2.152,600 A-shares have been repurchased
Gelonghui Group (000513.SZ) announced on March 4, 2024, that as of February 29, 2024, the company had repurchased a total of 2.152,600 shares of the company's A-shares through centralized bidding transactions, accounting for 0.23% of the company's total share capital. The highest purchase price was RMB 35.15 yuan/share, the lowest price was RMB 32.95 per share, and the total amount of capital used was RMB 73.436,500 (excluding transaction fees).
Livzon Pharmaceuticals (01513.HK): As of February 29, a total of 2.4763 million H shares have been repurchased
On March 4, GLONGHUI Pharmaceutical (01513.HK) announced that as of February 29, 2024, the company had repurchased a total of 2,476,300 shares of the company's H shares, accounting for 0.27% of the company's total share capital. The highest purchase price was HK$25.15 per share, the lowest price was HK$23.05 per share, and the total amount of capital used was HK$60363.26 million (excluding transaction fees).
Livestock Pharmaceuticals (01513.HK) plans to hold a board meeting on March 28 to approve annual results
Gelonghui, Feb. 28, 丨 Lizhu Pharmaceutical (01513.HK) issued an announcement. The board of directors is pleased to hold a board meeting on March 28, 2024 (Thursday) to review and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023, consider the proposed payment of a final dividend (if applicable) and deal with other matters (if any).
麗珠醫藥：董事會會議召開日期
Analysis
Price Target
No Data
